鶹Ժ


Lab-made sugar-coated particle reduces COVID-19 infection rates by 98.6% in human cell tests

Lab-made sugar-coated particle blocks COVID-19 infection—possible new treatment on the horizon
Deposited cryo-electron microscopy structures (see PDB entries) of the spike (S) protein trimer with all three RBDs in the down or up conformation shown in the left and right column, respectively. The S-protein is shown in grey, and the RBD in green except its receptor binding motif (RBM) that forms direct contacts with ACE2 is highlighted in red. The N-terminal domain (NTD) of one monomer of the S-protein is shown in orange only in the left column. The center-of-mass distance between two RBMs, dRBM, is mentioned for each conformation. Credit: Small (2025). DOI: 10.1002/smll.202500719

Research led by a Swansea University academic has revealed a synthetic glycosystem—a sugar-coated polymer nanoparticle—that can block COVID-19 from infecting human cells, reducing infection rates by nearly 99%.

The glycosystem is a specially designed particle that mimics found on . These sugars, known as polysialosides, are made of repeating units of sialic acid—structures that viruses often target to begin . By copying this structure, the acts as a decoy, binding to the 's spike protein and preventing it from attaching to real cells.

Unlike vaccines, which trigger immune responses, this molecule acts as a physical shield, offering a novel approach to infection prevention.

Using advanced lab techniques to measure molecular interactions and simulate virus binding, researchers found that the glycosystem binds to the virus 500 times more strongly than a similar compound containing sulfates but no sugars. It was also effective at very low doses and worked against both the original SARS-CoV-2 strain and the more infectious D614G variant.

Tests on human lung cells showed a 98.6% reduction in infection when the molecule was present. Crucially, the research highlighted that its effectiveness stems not just from its charge, but from its precise sugar structure—giving this glycosystem its powerful infection-blocking capability.

Published in Small, is the result of a collaboration between Swansea University, Freie Universität Berlin, and Charité—Universitätsmedizin Berlin.

As the main corresponding author and research supervisor, Dr. Sumati Bhatia, Senior Lecturer in Chemistry at Swansea University, said, "Leading this research, alongside our international partners, has been incredibly rewarding. It opens a new direction for using glycosystems as a therapeutic strategy against SARS-CoV-2 and could lay the foundation for a new class of antiviral therapies to protect those most at risk."

The team is now preparing for further biological testing in high-containment laboratories to assess the molecule's effectiveness against multiple virus strains.

This breakthrough could pave the way for antiviral nasal sprays, surface disinfectants, and treatments to protect , offering a new line of defense against COVID-19 and future pandemics.

More information: Vinod Khatri et al, Polysialosides Outperform Sulfated Analogs for Binding with SARS‐CoV‐2, Small (2025).

Journal information: Small

Provided by Swansea University

Citation: Lab-made sugar-coated particle reduces COVID-19 infection rates by 98.6% in human cell tests (2025, August 11) retrieved 11 August 2025 from /news/2025-08-lab-sugar-coated-particle-covid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Blocking spike captors to counter COVID

1 shares

Feedback to editors